Vaccination against respiratory tract pathogens in primary immune deficiency patients receiving immunoglobulin replacement therapy.

Makbule Seda Bayrak Durmaz, Reyhan Yıldız, Göksal Keskin, Seda Altıner
{"title":"Vaccination against respiratory tract pathogens in primary immune deficiency patients receiving immunoglobulin replacement therapy.","authors":"Makbule Seda Bayrak Durmaz, Reyhan Yıldız, Göksal Keskin, Seda Altıner","doi":"10.5578/tt.202401813","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inborn errors of immunity (IEI) increase morbidity and mortality risks, particularly from respiratory tract infections. Hence, vaccination becomes pivotal for IEI patients. This study aims to examine the vaccination and respiratory tract infection rates in a diverse IEI patient cohort undergoing immunoglobulin replacement therapy (IGRT).</p><p><strong>Materials and methods: </strong>We retrospectively evaluated IEI patients on IGRT at a tertiary care center. Data on vaccinations and respiratory infections were extracted from medical records.</p><p><strong>Result: </strong>: The study included 33 patients (mean age= 37.7 ± 11.4 years; 17 male). The most common clinical phenotype in our cohort was primary antibody deficiencies (90.9%). Only two patients had a genetic diagnosis, both of whom were brothers diagnosed with Wiskott-Aldrich syndrome (WAS). Almost half (48.5%) of our patients had bronchiectasis and 81.8% were on prophylactic antibiotics. All patients with IEI included in the study were regularly receiving IGRT. The vaccination rate of patients against respiratory tract infections was 42.4%, 57.6%, and 78.8% for influenza, pneumococcus, and COVID-19, respectively. Only one patient (7.1%) who received the influenza vaccine developed an upper respiratory tract infection. However, viral panel analysis could not be performed for this patient as they did not present to the hospital. The COVID-19 vaccination rate was notably higher than that of other vaccines, likely due to increased awareness during the pandemic, aided by public advisories and media influence.</p><p><strong>Conclusions: </strong>We observed higher vaccination rates for the COVID-19 vaccine compared to other vaccines (influenza and pneumococcal vaccines). Although we observed the potential impact of social and governmental influence in increasing vaccination rates, it is crucial to acknowledge that vaccination decisions in IEI patients must be individualized.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 1","pages":"1-8"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390071/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberkuloz ve toraks","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5578/tt.202401813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Inborn errors of immunity (IEI) increase morbidity and mortality risks, particularly from respiratory tract infections. Hence, vaccination becomes pivotal for IEI patients. This study aims to examine the vaccination and respiratory tract infection rates in a diverse IEI patient cohort undergoing immunoglobulin replacement therapy (IGRT).

Materials and methods: We retrospectively evaluated IEI patients on IGRT at a tertiary care center. Data on vaccinations and respiratory infections were extracted from medical records.

Result: : The study included 33 patients (mean age= 37.7 ± 11.4 years; 17 male). The most common clinical phenotype in our cohort was primary antibody deficiencies (90.9%). Only two patients had a genetic diagnosis, both of whom were brothers diagnosed with Wiskott-Aldrich syndrome (WAS). Almost half (48.5%) of our patients had bronchiectasis and 81.8% were on prophylactic antibiotics. All patients with IEI included in the study were regularly receiving IGRT. The vaccination rate of patients against respiratory tract infections was 42.4%, 57.6%, and 78.8% for influenza, pneumococcus, and COVID-19, respectively. Only one patient (7.1%) who received the influenza vaccine developed an upper respiratory tract infection. However, viral panel analysis could not be performed for this patient as they did not present to the hospital. The COVID-19 vaccination rate was notably higher than that of other vaccines, likely due to increased awareness during the pandemic, aided by public advisories and media influence.

Conclusions: We observed higher vaccination rates for the COVID-19 vaccine compared to other vaccines (influenza and pneumococcal vaccines). Although we observed the potential impact of social and governmental influence in increasing vaccination rates, it is crucial to acknowledge that vaccination decisions in IEI patients must be individualized.

为接受免疫球蛋白替代疗法的原发性免疫缺陷患者接种呼吸道病原体疫苗。
导言:先天性免疫错误(IEI)会增加发病率和死亡率,尤其是呼吸道感染。因此,接种疫苗对 IEI 患者至关重要。本研究旨在调查接受免疫球蛋白替代疗法(IGRT)的不同 IEI 患者群体的疫苗接种率和呼吸道感染率:我们对一家三级医疗中心接受 IGRT 治疗的 IEI 患者进行了回顾性评估。从医疗记录中提取了有关疫苗接种和呼吸道感染的数据:研究包括 33 名患者(平均年龄= 37.7 ± 11.4 岁;17 名男性)。我们队列中最常见的临床表型是原发性抗体缺乏(90.9%)。只有两名患者被确诊为遗传病,他们兄弟俩都被确诊患有威斯科特-阿尔德里奇综合征(WAS)。近一半的患者(48.5%)患有支气管扩张,81.8%的患者使用预防性抗生素。研究中的所有 IEI 患者均定期接受 IGRT 治疗。患者接种流感、肺炎球菌和 COVID-19 疫苗预防呼吸道感染的比例分别为 42.4%、57.6% 和 78.8%。只有一名接种了流感疫苗的患者(7.1%)发生了上呼吸道感染。不过,由于该患者没有到医院就诊,因此无法对其进行病毒面板分析。COVID-19疫苗的接种率明显高于其他疫苗,这可能是由于在大流行期间,人们的意识在公众建议和媒体影响的帮助下得到了提高:我们观察到 COVID-19 疫苗的接种率高于其他疫苗(流感疫苗和肺炎球菌疫苗)。尽管我们观察到社会和政府影响对提高疫苗接种率的潜在影响,但必须承认,IEI 患者的疫苗接种决定必须因人而异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信